Myeloma News and Research

RSS

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Seattle Genetics, Inc. announced today that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of superior complete response rate in the dacetuzumab combination arm as compared to the placebo combination arm.

5 Oct 2009

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Quest PharmaTech Inc. ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc. ("Paladin").

3 Oct 2009

Leading oncology experts to discuss management of hematological malignancies

Oncology experts from leading cancer organizations from around the country, including the John Theurer Cancer Center, MD Anderson Cancer Center, the Mayo Clinic, Dana Farber Cancer Institute and the National Cancer Institute, will discuss trends in patient care, novel therapies through clinical trials and emerging concepts in the management of hematological malignancies.

23 Sep 2009

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.

22 Sep 2009

Investigative drug hampers the survival of non-Hodgkin lymphoma cells

An investigative drug deprived non-Hodgkin lymphoma cells of their ability to survive too long and multiply too fast, according to an early study published recently in the journal Experimental Hematology.

22 Sep 2009

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA).

21 Sep 2009

Multiple Myeloma Research Foundation focuses on effective cancer treatment

The Multiple Myeloma Research Foundation (MMRF) today announced that American figure skating legend and Olympic gold medalist Scott Hamilton will serve as Master of Ceremonies at the 13th Annual MMRF Fall Gala, on Saturday, Oct. 24, 2009, at the Hyatt Regency in Greenwich, Conn.

19 Sep 2009

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

19 Sep 2009

Amgen to present its four Phase 3 clinical trial results

Amgen today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.

16 Sep 2009

FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma

Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan-Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. In August, the Company announced that it had reached an agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial in relapsed/refractory multiple myeloma and that the study is expected to start by year-end.

16 Sep 2009

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

AEterna Zentaris Inc., ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc., its partner and licensee for perifosine in the North American market, has received orphan-drug designation for this compound from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.

16 Sep 2009

Loyola University receives funds to renovate bone marrow transplant unit

Loyola University Medical Center has received a $2 million matching grant from The Coleman Foundation to renovate the hospital's nationally known bone marrow transplant unit. Intended to encourage private donations for the project, the grant will match gifts up to $2 million on a dollar for dollar basis, through August 2010.

15 Sep 2009

Celldex commences dosing patients in Phase 1/2 study of its CDX-1401 vaccine candidate

Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the first patient has been dosed in a Phase 1/2 study of its vaccine candidate, CDX-1401, in patients with malignant solid tumors that express NY-ESO-1. CDX-1401 is a fully human monoclonal antibody designed to selectively deliver the NY-ESO-1 antigen to dendritic cells to generate a robust immune response against cancer cells expressing NY-ESO-1.

14 Sep 2009

Ascent Therapeutics demonstrates Pepducin efficacy

Ascent Therapeutics announced today that the Company has demonstrated efficacy in preclinical models in two Pepducin projects. One of the projects targets CXCR4, a key regulator of stem cell and inflammatory cell homeostasis. A second project has yielded the first potent Pepducin agonists for an undisclosed cardiovascular target.

11 Sep 2009

FDA approves Supplemental New Drug Application for DOXIL

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

10 Sep 2009

Roche Group and ImmunoCellular Therapeutics sign research agreement regarding ICT-69 antibody

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group (SWX: ROG.VX; RO.S, OTCQX: RHHBY), one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.

10 Sep 2009

Five Clinical Research Units established

With the establishment of five new Clinical Research Units the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) hopes to give a further boost to clinical research in Germany and drive progress in the scientific investigation and possibilities for the treatment of disease.

7 Sep 2009

Germany’s BMBF awards NOXXON grant for developing Spiegelmer NOX-A12

NOXXON Pharma AG (NOXXON), clinical-stage developer of L-RNA based scaffolds (Spiegelmers®) that bind their targets conceptually similar to antibodies, announced today that the company was awarded a research grant from Germany’s Federal Ministry of Education and Research (BMBF) under the ministry’s small and medium enterprise innovation initiative (“KMU-Innovativ”).

3 Sep 2009

Millennium's sNDA to be reviewed by the FDA

The Takeda Oncology Company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) based on long- term overall survival (OS) data from the landmark VISTA1 trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

3 Sep 2009

Boron-based molecules can be used as new pharmacophores

Chemists and biologists have successfully demonstrated that specially synthesized boron compounds are readily accepted in biologically active enzymes, a move that, they say, is a proof of concept that could lead to new drug design strategies.

3 Sep 2009